This startup wants to make enterprise software look more like a prompt https://t.co/lUkSCf8C9z ...

Hey, I'm Kramer. Welcome to Mad Money. Welcome to Cray America.Other people want to make friends. I just want to make you money. My job is not just to entertain, but to educate and teach you.So call me at 1800 743 CBC. You can tweet me at Jim Kramer. There is a reason I always hesitate to recommend the hottest stocks in the market, the ones with the parabolic moves, the monstrous one day gains.Why. Cuz days like today, that's why. days where you can lose so much money in the highf flyers more than you made ...

Industry Trend - Enterprise software's future envisions SaaS for core business workflow [1] - Agents are built on top of the SaaS platform [1]

Market Dynamics - Adobe attempted to acquire Figma, a design software company specializing in AI design software, for $20 billion, but the deal was unsuccessful [1] - Analysts are largely neutral on Figma, possibly influenced by its popularity among Gen Z investors [1] Investment Analysis - The speaker expresses surprise at the stock's performance, suggesting it may not be sustainable [2] - Enterprise software, once dominant, is likened to dinosaurs, implying a decline in relevance [2][3]

Stock Recommendations & Analysis - By Marin's orphan drug model is losing its effectiveness [1] - Union Pacific stock is a buy due to onshoring and tariffs [4][5] - GitLab (GTL) is not favored in the current enterprise software environment due to high expenses, Oracle is preferred because of data center [5][6] - AR Pharmaceuticals is a potentially good investment due to its epinephrine nasal spray and recent contract, but it's considered a flyer dependent on technology acquisition [8][9] - Newscale is currently at a high price, and a stock offering would be a better buying opportunity [10][11] Company Specific Information - Arlo Technologies (home security cameras) is approaching its all-time high, but it requires further analysis [2] - AR Pharmaceuticals received FDA and EU approval for an epinephrine nasal spray and has a $145 million upfront payment contract [7][8] - Newscale is being discussed, but its current price is considered high [10] General Market Sentiment - The orphan drug model may not be as effective as it once was [1] - Onshoring and tariffs are expected to positively impact the transport industry, particularly Union Pacific [4] - Collaborative enterprise software stocks are currently not favored due to high expenses, data center companies are preferred [6]